What 4 Analyst Ratings Have To Say About Evolent Health
Portfolio Pulse from Benzinga Insights
Evolent Health (NYSE:EVH) received mixed analyst ratings, with 1 bullish and 3 somewhat bullish ratings. Analysts set a 12-month price target average of $37.75, up from $35.00. Recent actions include JP Morgan raising its target to $45.00 and JMP Securities lowering it to $31.00. Evolent Health shows strong financial performance with a 37.94% revenue growth rate and a balanced debt approach.
August 19, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolent Health received mixed analyst ratings, with a 12-month price target average of $37.75, indicating a positive outlook. The company shows strong financial performance with a 37.94% revenue growth rate.
The mixed analyst ratings, with a majority being somewhat bullish, and an increased average price target suggest a positive short-term outlook for Evolent Health. The company's strong financial performance, including a significant revenue growth rate, supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100